Lapatinib in Treating Patients With Unresectable Liver or Biliary Tract Cancer
Tracking Information | |||||
---|---|---|---|---|---|
First Received Date ICMJE | April 5, 2005 | ||||
Last Updated Date | September 5, 2012 | ||||
Start Date ICMJE | October 2005 | ||||
Primary Completion Date | May 2009 (final data collection date for primary outcome measure) | ||||
Current Primary Outcome Measures ICMJE |
Response rate every 2 months after completion of study treatment [ Designated as safety issue: No ] | ||||
Original Primary Outcome Measures ICMJE |
Response rate every 2 months after completion of study treatment | ||||
Change History | Complete list of historical versions of study NCT00107536 on ClinicalTrials.gov Archive Site | ||||
Current Secondary Outcome Measures ICMJE |
|
||||
Original Secondary Outcome Measures ICMJE |
|
||||
Current Other Outcome Measures ICMJE | |||||
Original Other Outcome Measures ICMJE | |||||
Descriptive Information | |||||
Brief Title ICMJE | Lapatinib in Treating Patients With Unresectable Liver or Biliary Tract Cancer | ||||
Official Title ICMJE | A Phase II Study of Efficacy and Tolerability of GW572016 in Patients With Advanced Hepatocellular and Biliary Carcinomas | ||||
Brief Summary | RATIONALE: Lapatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well lapatinib works in treating patients with unresectable liver or biliary tract cancer. |
||||
Detailed Description | OBJECTIVES: Primary
Secondary
OUTLINE: This is a multicenter study. Patients receive oral lapatinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. PROJECTED ACCRUAL: A total of 70 patients will be accrued for this study within 1 year. |
||||
Study Type ICMJE | Interventional | ||||
Study Phase | Phase 2 | ||||
Study Design ICMJE | Masking: Open Label Primary Purpose: Treatment |
||||
Condition ICMJE |
|
||||
Intervention ICMJE | Drug: lapatinib ditosylate | ||||
Study Arm (s) | |||||
Publications * | Bekaii-Saab T, Markowitz J, Prescott N, Sadee W, Heerema N, Wei L, Dai Z, Papp A, Campbell A, Culler K, Balint C, O'Neil B, Lee RM, Zalupski M, Dancey J, Chen H, Grever M, Eng C, Villalona-Calero M. A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. Clin Cancer Res. 2009 Sep 15;15(18):5895-901. Epub 2009 Sep 8. | ||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||
Recruitment Information | |||||
Recruitment Status ICMJE | Completed | ||||
Estimated Enrollment ICMJE | 70 | ||||
Completion Date | |||||
Primary Completion Date | May 2009 (final data collection date for primary outcome measure) | ||||
Eligibility Criteria ICMJE | DISEASE CHARACTERISTICS:
PATIENT CHARACTERISTICS: Age
Performance status
Life expectancy
Hematopoietic
Hepatic
Renal
Cardiovascular
Gastrointestinal
Other
PRIOR CONCURRENT THERAPY: Biologic therapy
Chemotherapy
Endocrine therapy
Radiotherapy
Surgery
Other
|
||||
Gender | Both | ||||
Ages | 18 Years and older | ||||
Accepts Healthy Volunteers | No | ||||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||||
Location Countries ICMJE | United States | ||||
Administrative Information | |||||
NCT Number ICMJE | NCT00107536 | ||||
Other Study ID Numbers ICMJE | CDR0000420830, OSU-0447, NCI-6696 | ||||
Has Data Monitoring Committee | |||||
Responsible Party | Tanios Bekaii-Saab, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center | ||||
Study Sponsor ICMJE | Ohio State University Comprehensive Cancer Center | ||||
Collaborators ICMJE | National Cancer Institute (NCI) | ||||
Investigators ICMJE |
|
||||
Information Provided By | National Cancer Institute (NCI) | ||||
Verification Date | June 2009 | ||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |